Patients with idiopathic constipation show increased serum antibody titers against Staphylococcus aureus and E
Anyone considering it should consult a qualified clinician before use
Consumer insights professionals should use this opportunity to prepare themselves not only for future GLP-1 growth but also for future health and weight loss trends
Tirzepatide, a GLP-1/GIP dual agonist, demonstrated impressive NASH resolution rates of up to 73.3% in the SYNERGY-NASH trial
During this initial meeting, you'll sit down with one of our experienced medical providers who will conduct a comprehensive health assessment, discuss your goals, and answer all of your questions
Rapid weight loss can cause temporary hair loss, but its not directly caused by the medication, says Pinto